News | Artificial Heart | February 10, 2021

FDA OKs Use New Version of Carmat Artificial Heart in U.S. Early Feasibility Study

First enrollment in Carmat study expected in first part of 2021

The Carmat artificial heart

February 10, 2021 - The U.S. Food and Drug Administration (FDA) has granted artificial heart developer Carmat approval to use the new version of its artificial heart in its U.S. early feasibility study (EFS). This new version of the device includes improvements in the prosthesis and the wearable system based on clinical experience gained in the PIVOTAL study. The company believes that this latest version should further improve patient safety and quality of life.

Carmat's device is designed to fulfill an unmet medical need by providing a therapeutic alternative to heart transplants in people suffering from end-stage biventricular heart failure.

The company said it expects the first enrollments in the EFS in Q1 of 2021.

Carmat obtained the approval from the Centers for Medicare and Medicaid Services (CMS) for the reimbursement of the device and associated services within the framework of this study in May 2020.

"We are pleased to provide this new version of our artificial heart, which is similar to our CE-marked product, to the U.S. study centers," said Stéphane Piat, chief executive officer of Carmat. "Despite the COVID-19 pandemic, we were able to train and initiate three of them before the end of 2020. These centers are now ready to enroll patients. We also intend to pursue the training and initiation of additional selected centers."

The Carmat total artificial heart is composed of the implantable bioprosthesis and its portable external power supply system to which it is continuously connected. The goal for the device is to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from irreversible end-stage heart failure, the most seriously affected of the 20 million patients with this progressive disease in Europe and the United States.

The result of combining two types of unique expertise: the medical expertise of Professor Alain Carpentier, known throughout the world for inventing Carpentier-Edwards heart valves, which are the most used in the world, and the technological expertise of Airbus Group, world aerospace leader.

The device uses highly biocompatible materials, offers a unique self-regulation system and its pulsatile nature are expected to reduce or eliminate the risk of rejection by patients bodies.

For more information: www.carmatsa.com

 

Related Carmat Content:

Carmat to Initiate FDA U.S. Feasibility Study of Total Artificial Heart

First Implantation of Carmat Total Artificial Heart in Denmark

Carmat Announces Start of the PIVOTAL Study
 

 

Related Content

The Carmat system, an experimental artificial heart includes an autoregulation control mechanism, or Auto-Mode, that can adjust to the changing needs of patients treated for end-stage heart failure. Outcomes in the first series of patients managed with the new heart replacement pump in Auto-Mode are presented in the journal of the American Society for Artificial Internal Organs (ASAIO). 

The Carmat artificial heart technology.

News | Artificial Heart | June 23, 2021
June 18, 2021 – An experimental artif...
News | Artificial Heart | May 27, 2020
May 27, 2020 — Carmat, a developer of the of a next generation advanced total artificial heart, announces the first i
CorInnova Awarded 2017 InnoSTARS Prize for EpicHeart Soft Robotic Heart Assist Device
News | Artificial Heart | December 11, 2017
CorInnova Inc. recently announced it was awarded second prize in the “2017 InnoSTARS” life science competition for its...
CorInnova Awarded Seminal Patent for Minimally Invasively-Delivered Soft Robotic Heart Device
News | Artificial Heart | October 27, 2017
CorInnova Inc. announced it has received notice of allowance of a seminal patent to protect its intellectual property...
SynCardia, Chapter 11 reorganization, sale, Total Artificial Heart
News | Artificial Heart | September 13, 2016
August 29, 2016 — SynCardia Systems, manufacturer of the...
Carmat, bioprosthetic artificial heart, PIVOTAL study, first implantation, heart failure
News | Artificial Heart | September 09, 2016
Carmat announced that the first implantation of its bioprosthetic artificial heart within the framework of the PIVOTAL...
SynCardia Total Artificial Heart, TAH-t, documentary, Retro Reports, The New York Times
News | Artificial Heart | March 24, 2016
March 24, 2016 — A new documentary produced by Retro Report for The New York Times looks at the history and
Bryan Tyo, Baylor University Medical Center, bridge to transplant, Total Artificial Heart
News | Artificial Heart | March 18, 2016
A surgical team at Baylor University Medical Center at Dallas successfully performed a heart transplant on a patient...